Table 1.

Summary of methods for identifying pre-symptomatic disease onset, symptomatic disease onset and lifespan.

Evaluation methods	Age in days (range)
Pre-symptomatic disease onset
Peak bodyweighta	143.5 ± 12.9 (114–163)
Distance traveled in PASb	151.3 ± 19.0 (118–176)
Ascending timec	159.6 ± 13.3 (138–173)
Symptomatic disease onset
Observable motor deficitsd	167.6 ± 15.8 (138–187)
Rearing events in PASe	165.0 ± 15.5 (138–186)
Resting time in PASf	174.3 ± 12.5 (156–191)
End-stage disease
Lifespang	188.7 ± 15.2 (165–207)

Mean ± SD. ALS transgenic rats (n=10). Male:female ratio is 1:1.

^aMax weight prior to a constant decline

^bTotal distance traveled ≤ 6500 cm

^cAverage climbing time ≥ 1.8 sec.

^dMotor score of 4

^eTotal rearing events ≤ 60 events

^fTotal resting time ≥ 450 sec.

^gMotor score of 0